NEW YORK (GenomeWeb News) – Diagnostics developer Tethys Bioscience said today that it has bought Lipomics Technologies, a metabolite-profiling firm, for an undisclosed sum.
 
Tethys, which earlier this year began selling a test for diabetes risk, said the acquisition will help it to develop new tests to predict the likelihood of developing chronic diseases. Currently, Emeryville, Calif.-based Tethys is developing a test to predict the likelihood that a person will experience osteoporotic bone fracture or a major cardiac event.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.